HYOGO, Japan–(BUSINESS WIRE)–JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in Kuwait.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.